

# Chapter 13

## Mature T/NK Proliferations / Lymphomas and HL: Diagnostic Approach

### ABSTRACT

*“T and NK-cell lymphoid proliferations and lymphomas” comprise nine groups with distinct cell origins, differentiation states, clinical features, localization, and cytomorphology. Most correspond to specific T or NK lineage. Still, few have a hybrid or indeterminate phenotype, including extranodal NK and T-cell lymphoma, EBV+ nodal T/NK-cell lymphoma, chronic active EBV disease, and severe mosquito bite allergy. The distinction between T- and NK cells is sometimes unclear. The main categories are Mature T-cell and NK-cell leukemias, Primary cutaneous T-cell lymphoid proliferations and lymphomas (CTCL), Intestinal T- and NK-cell lymphoid proliferations and lymphomas, Nodal T-Follicular Helper Cell Lymphomas, Peripheral T-cell lymphomas (PTCLs), EBV-related mature T-cell and NK-cell neoplasms, and Extranodal NK/T-cell lymphoma (ENKTL). HL comprises classical HL (cHL) and nodular lymphocyte predominant HL (NLPHL) subtypes.*

### INTRODUCTION

The main categories of mature T-cell and NK-cell lymphomas in the WHO 5<sup>th</sup> edition classification have been extended to include more entities with refined molecular pathogenesis and diagnostic criteria. (Alaggio et al., 2022).

Recently, the heterogeneity of Hodgkin lymphoma has been highlighted. While classic Hodgkin lymphoma (CHL) remains unchanged, nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is now renamed nodular lymphocyte predominant B cell lymphoma (NLPBL) in recognition of the distinct pathologic, biologic, and clinical differences. (Tousseyn et al., 2023).

This chapter aims to explore the rationale of recent biological classification, molecular pathogenesis, and diagnostic approaches to the T/NK and HL. The implications on risk stratification and therapeutic decisions on these types of lymphoma with the role of novel targeted therapy. These objectives will be discussed through the following sections:

A. Mature T-cell and NK-cell lymphomas in the WHO 5<sup>th</sup> edition classification (Alaggio et al., 2022), including leukemic and non-leukemic entities

B. Hodgkin’s lymphoma: Classic and Nodular lymphocyte predominance types

DOI: 10.4018/978-1-6684-5818-1.ch013

**A. Mature T/NK Proliferations/Lymphomas**

The main categories of mature T-cell and NK-cell lymphomas in the WHO5 classification (Alaggio et al., 2022) are grouped into Leukemic and Non-leukemic types.

**MATURE T-CELL AND NK-CELL LEUKEMIAS**

Mature T- and NK-cell neoplasms present primarily as leukemia and include the following entities:

1. ***T-prolymphocytic leukemia (T-PLL)*** is rare accounting for ~2% of all small lymphocytic leukemias in adults with a median age of 61. It typically presents with splenomegaly, lymphadenopathy, and leucocytosis frequently  $>100 \times 10^9/l$ . Less commonly, other organs and skin are involved. Up to 30% of patients are asymptomatic at diagnosis. (Sabattini, 2022). It arises from mature, antigen-experienced, non-conventional memory T-cells.

Most T-PLL have aberrant *TCL1A* or *MTCP1* protooncogenes expression, leading to overexpression of *TCL1* and non-productive TCR-A rearrangement and the transition of naïve T-cells into an expanding pool of memory T cells. The TCR-mediated activation is the genetic hallmark of TPLL. Protein kinase B Akt1 activation and nuclear transport promote cell proliferation. (Shi & Jevremovic, 2022)

The diagnostic criteria and workup of T-PLL include major and minor criteria as outlined in Table 1. The recommended workup is summarized in Table 14.2 (Staber et al., 2019).

*Table 1. Requirements to establish the diagnosis of T-PLL (Staber et al., 2019)*

Major Criteria	Minor Criteria (At Least One Required)
$>5 \times 10^9/L$ TPLL cells in peripheral blood or bone marrow	Abnormalities involving chromosome 11 (11q22.3; <i>ATM</i> )
T-cell clonality by PCR for TRB/TRG or by flow cytometry	Chromosome 8 abnormalities: <i>idic(8)(p11)</i> , <i>t(8;8)</i> , trisomy 8q
Abnormalities of 14q32 or Xq28 genes OR expression of <i>TCL1A/B</i> , or <i>MTCP1</i> *	Abnormalities in chromosomes 5,12,13, 22, or complex karyotype
	Involvement of T-PLL specific site (e.g., splenomegaly, effusions)

*Cases without *TCL1A*, *TCL1B*, or *MTCP1* rearrangement or their respective overexpression constitute a *TCL1*-family negative T-PLL.*

*Table 2. Recommended workup for patients with T-PLL (Staber et al., 2019)*

Assessments	General Practice	Clinical Trials
<b>Initial Diagnosis</b>		
History, physical examination	Always	Always
Blood count and differential count	Always	Always
Bone marrow aspirate and biopsy	When clinically indicated	Desirable
Biopsy or aspirate of the suspected involved site	When clinically indicated	Desirable
Immunophenotyping of blood lymphocytes	Always	Always
T-cell receptor rearrangement (TRB, TRG)	Always	Always
chromosome banding analysis	Desirable	Desirable

continued on following page

30 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage:

[www.igi-global.com/chapter/mature-tnk-proliferationslymphomas-and-hl/350015](http://www.igi-global.com/chapter/mature-tnk-proliferationslymphomas-and-hl/350015)

## Related Content

---

### Receptor-Based Combinatorial Nanomedicines: A New Hope for Cancer Management

Harshita Abul Barkat, Md Abul Barkat, Mohamad Taleuzzaman, Sabya Sachi Das, Md. Rizwanullah and Hazrina Ab Hadi (2021). *Handbook of Research on Advancements in Cancer Therapeutics* (pp. 339-355). [www.irma-international.org/chapter/receptor-based-combinatorial-nanomedicines/267048](http://www.irma-international.org/chapter/receptor-based-combinatorial-nanomedicines/267048)

### Hashimoto's Ophthalmopathy

(2020). *Diagnosing and Managing Hashimoto's Disease: Emerging Research and Opportunities* (pp. 141-157). [www.irma-international.org/chapter/hashimotos-ophthalmopathy/243791](http://www.irma-international.org/chapter/hashimotos-ophthalmopathy/243791)

### The Magic of Monologue: Healing Depression Through Drama

Sue Gauthier-Pin (2019). *Healing Through the Arts for Non-Clinical Practitioners* (pp. 75-85). [www.irma-international.org/chapter/the-magic-of-monologue/211667](http://www.irma-international.org/chapter/the-magic-of-monologue/211667)

### Ageing and Mental Health: A Psychological Aspect of Later Life

Neelam Verma (2018). *Handbook of Research on Geriatric Health, Treatment, and Care* (pp. 369-392). [www.irma-international.org/chapter/ageing-and-mental-health/201393](http://www.irma-international.org/chapter/ageing-and-mental-health/201393)

### Natural Products and Their Bioactive Compounds as Breast Cancer Therapeutics

Monika Rezacova (2022). *Handbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics* (pp. 27-44). [www.irma-international.org/chapter/natural-products-and-their-bioactive-compounds-as-breast-cancer-therapeutics/299795](http://www.irma-international.org/chapter/natural-products-and-their-bioactive-compounds-as-breast-cancer-therapeutics/299795)